SDK BioTechnologies develops an enabling ground-breaking core technology for biomarker disease diagnostics.

This breakthrough solves the cross-reactivity issues in multiplex assays, leading to:
  — reduced assay development time
  — increased assay sensitivity
  — increased diagnostic accuracy
  — enabled flexibility in diagnostics

It also provides remarkable technical and commercial potential thanks to its low cost core components and its compatibility with low- and high-throughput sample workflows